Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy

doi:10.3748/wjg.v27.i11.1101

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7865)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

435

WORD

154

HTML

3659

Figures (1-4)

424

Tables (1-3)

285

Sum=4957

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

591

Download

816

Sum=1407

Publishing Process of This Article

Item

Count

Browse

437

Download

1064

Sum=1501

Mar 21, 2021 (publication date) through Sep 22, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Mar 21, 2021; 27(11): 1101-1116
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1101

Table 1 Data regarding the patients’ baseline characteristics

	Chronic hepatitis B patients		Hepatitis B cirrhosis patients
	Observation group (n = 362)	Control group (n = 203)	Observation group (n = 96)	Control group (n = 129)
Sex: Males (%)	291 (80.38)	175 (86.20)^a	74 (77.08)	119 (92.24)^a
E antigen-positive patients (%)	198 (54.69)	123 (60.59)^a	30 (31.25)	32 (24.80)
Age (yr)	33 (25-40)	39 (32-46)^a	59.50 (48-67)	48 (41-58)
Median follow-up time	10 (7-14)	8 (6-9)^a	7 (5-8)	7 (6-8)
HBV-DNA (log)	7.14 (5.92-7.70)	6.76 (5.63-7.29)	4.77 (4.37-5.53)	4.92 (4.06-5.57)
ALT	188.62 (141.70-296.55)	185.50 (135.01-260.25)	98.73 (75.91-121.73)	110.00 (78.10-202.00)
AST	132.14 (100.00-173.57)	135.00 (110.00-215.00)	53.15 (40.77-122.58)	76.00 (49.00-105.00)
TB	27.00 (21.30-36.50)	28.50 (21.00-41.25)	39.10 (33.00-45.00)	37.00 (18.00-51.00)^a
ALB			32.00 (26.00-37.70)	36.00 (33.50-37.00)
PLT			99.50 (58.00-120.00)	107.00 (102.00-119.00)^a
Diabetes (%)	39 (10.77)	21 (10.34)	21 (21.87)	26 (20.15)
Hypertension (%)	29 (8.01)	18 (8.86)	23 (23.95)	25 (19.37)
Family history of hepatocellular carcinoma (%)	21 (5.80)	10 (4.97)	19 (19.76)	27 (20.93)
REACH-B score	10 (8-12)	10 (8-12)

^aP < 0.05 compared with the observation group. HBV: Hepatitis B virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TB: Total bilirubin; ALB: Albumin; PLT: Platelet.

Citation: Jiang XY, Huang B, Huang DP, Wei CS, Zhong WC, Peng DT, Huang FR, Tong GD. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. World J Gastroenterol 2021; 27(11): 1101-1116
URL: https://www.wjgnet.com/1007-9327/full/v27/i11/1101.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i11.1101